In recent years, targeted therapy has emerged as a promising option for certain patients with uterine cancer, focusing on specific molecules or pathways that cancer cells use to grow and survive, and drugs such as those targeting the HER2 protein or angiogenesis pathways that affect blood vessel formation can be particularly effective in selected cases when tumors express specific biomarkers, allowing for a more personalized treatment approach that may improve effectiveness while reducing damage to healthy cells. Immunotherapy has also become an important advancement in uterine cancer treatment, especially for patients with advanced or recurrent disease that does not respond well to traditional therapies, and these treatments work by stimulating the body’s own immune system to recognize and attack cancer cells, with immune checkpoint inhibitors such as those targeting PD-1 or PD-L1 showing encouraging results in tumors that are mismatch repair deficient or microsatellite instability-high, a genetic characteristic found in a subset of uterine cancers.
The identification of these molecular features through tumor testing has transformed treatment planning by allowing clinicians to match patients with therapies most likely to benefit them, highlighting the growing importance of precision medicine in gynecologic oncology. Fertility-sparing treatment is a highly specialized and carefully considered option for a small group of younger patients with early-stage, low-grade endometrial cancer who strongly desire future pregnancy, and it typically involves high-dose hormone therapy combined with close surveillance using imaging and endometrial sampling, with the understanding that definitive surgical treatment is usually recommended once childbearing is complete or if the cancer does not respond adequately to hormonal management. Supportive and palliative care is an essential component of uterine cancer treatment at all stages of the disease, focusing on symptom management, pain control, emotional support, nutritional guidance, and overall quality of life, and it can be provided alongside curative treatments or as the main focus of care in advanced cases, ensuring that patients’ physical, psychological, and social needs are addressed with compassion and respect.
Follow-up care after treatment is critical and typically includes regular physical examinations, imaging studies when indicated, and monitoring for symptoms of recurrence or treatment-related side effects, as early detection of recurrence can open the door to additional treatment options and better outcomes. Throughout the treatment journey, patient education, shared decision-making, and clear gastro intestinal cancer specialist between patients and healthcare providers play a vital role in empowering individuals to understand their diagnosis, treatment options, potential risks and benefits, and expected outcomes, enabling them to make informed choices that align with their values and life goals. Advances in research continue to improve uterine cancer treatment, with ongoing clinical trials exploring new drug combinations, novel targeted agents, immunotherapies, and less invasive surgical and radiation techniques, offering hope for improved survival rates, fewer side effects, and better quality of life for patients now and in the future, and as our understanding of the genetic and molecular basis of uterine cancer deepens, treatment strategies are becoming increasingly tailored, moving away from a one-size-fits-all approach toward more precise, effective, and patient-centered care that recognizes each individual’s unique situation and needs.
Uterine cancer treatment is a multifaceted and highly individualized process that depends on the type and stage of the cancer, the patient’s overall health, age, fertility considerations, genetic factors, and personal preferences, and it typically involves one or a combination of surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy, all coordinated by a multidisciplinary medical team to achieve the best possible outcome while preserving quality of life. In most cases, especially for endometrial cancer which is the most common form of uterine cancer, surgery is the primary and often first-line treatment, usually involving a total hysterectomy where the uterus is removed along with the cervix, and frequently accompanied by a bilateral salpingo-oophorectomy, which means removal of both ovaries and fallopian tubes to reduce the risk of cancer spread or recurrence, and during this procedure lymph nodes in the pelvis and sometimes around the aorta may also be sampled or removed to determine whether the cancer has spread beyond the uterus, a step that is critical for accurate staging and planning further treatment.